MedDataX Logo

Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

NCT ID: NCT05532475

Last Updated: 2024-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-12

Study Completion Date

2022-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cases

patient with retinal vein occlusion

measurement of vitreous level of tumor necrosis factor alpha

Intervention Type DIAGNOSTIC_TEST

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

control

cataract patient undergoing cataract surgery

measurement of vitreous level of tumor necrosis factor alpha

Intervention Type DIAGNOSTIC_TEST

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measurement of vitreous level of tumor necrosis factor alpha

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection

Exclusion Criteria

1. Diabetic patients.
2. Other causes of retinal vascular diseases.
3. Patients with history of treatment of retinal vein occlusion.
4. Previous intraocular surgery except cataract surgery performed 6 months before the study.
5. Subjects with severe systemic inflammatory diseases
6. Retinal vein occlusion secondary to retinal vasculitis.
7. All retinal pathologies.
8. Patients receiving Systemic steroids or Immunosuppressive therapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Ahmed Mohamed Attya

Lecturer of ophthalmology- faculty of medicine- Cairo University

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr ALainy University hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS-654-2021

Identifier Type: -

Identifier Source: org_study_id